Grafix® Demonstrates Overwhelming Efficacy in Landmark Stem Cell Study for the Treatment of Diabetic Foot Ulcers

Grafix closes three times as many wounds as standard of care - the largest relative improvement ever reported in a multi-center, randomized, controlled clinical trial for DFU

Osiris Therapeutics, Inc. (OSIR), reported today that its multi-center, randomized, controlled clinical trial comparing the safety and effectiveness of Grafix® to standard of care in patients with chronic diabetic foot ulcers had met the pre-specified stopping rules for overwhelming efficacy as determined by the data monitoring committee during a planned interim analysis. For the primary endpoint, 62% of patients receiving Grafix had complete wound closure compared to only 21% (p

Tekmira Initiates TKM-PLK1 Phase I/II Clinical Trial, Enrolling Patients With Advanced Gastrointestinal Neuroendocrine Tumors (GI-NET) or Adrenocortical Carcinoma (ACC)

Future Clinical Development Plans Outlined for Tekmira's Oncology Therapeutic, TKM-PLK1

Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has initiated a Phase I/II clinical trial with TKM-PLK1, its RNAi oncology therapeutic for the treatment of solid tumors.

Cardium Reports On New Excellagen-Based Stromal Cell Research For Wound Healing With Orbsen Therapeutics Under European FP7 REDDSTAR Diabetes Initiative

Cardium Therapeutics (NYSE MKT: CXM) today announced that it has entered into an agreement with Orbsen Therapeutics Ltd and the National University of Ireland, Galway, to utilize Cardium's Excellagen^® pharmaceutically-formulated gel as a delivery agent for Orbsen's proprietary stromal cell therapy in pre-clinical studies for the potential treatment of diabetic foot ulcers. The research is being conducted by the Regenerative Medicine Institute (REMEDI), at the National University of Ireland Galway (NUIG), a world-class biomedical research centre focused on mesenchymal stromal cell (MSC) research. The research initiative is funded by REDDSTAR, a European Union Framework 7 (EU FP7) research collaboration focused on treating diabetes and its complications with a defined MSC therapy and enlisting academic and industry partners throughout Europe in the program (www.reddstar.eu).

Verenium To Present At Two Upcoming Conferences

Verenium Corporation (VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that James Levine, Chief Executive Officer, and Janet Roemer, Chief Operating Officer, will present at two upcoming conferences.

Ms. Roemer will present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA.  The presentation is scheduled to begin at 2:00 p.m. ET. 

Mr. Levine will present at the upcoming Jefferies 2013 Global Industrials Conference in New York City on Monday, August 12, 2013. The presentation is scheduled to begin at 10:30 a.m. ET.